


References


Mediastinal germ cell tumour and myelodysplastic syndrome

Sir,

Nichols et al.1 have recently described 16 cases of haematological neoplasia associated with non-seminomatous mediastinal germ cell tumours and suggest that these neoplasms arise from a common progenitor cell.

We wish to report a 20 year old man with an enormous primary mediastinal germ cell tumour with histological evidence of yolk-sac elements in combination with teratoma, and high alpha-fetoprotein (AFP) serum levels (2130 ng/ml). He was treated with six courses sequentially of combinations of cisplatin, etoposide, ifosfamide and bleomycin with a partial response as measured by thoracic scan and the reduction of AFP levels to 190 ng/ml.

During the chemotherapy treatment, the patient developed persistent pancytopenia and a severe myelodysplastic syndrome with abnormal megakaryocytes in two bone marrow biopsies. The cytogenetic analysis demonstrated three abnormal clones: trisomy 1 with an extra marker chromosome, a second clone with, added to the first, a trisomy 18 and a third clone with an extra 8 chromosome. The karyotype yielded 48, XY, +1, + mar/49, XY, +1, +18, + mar/50, XY, +1, +8, +18, + mar.

In the patients who develop a chemotherapy or radiotherapy related leukaemia or myelodysplastic syndrome, the karyotype usually shows a hypodiploid modal number and abnormalities in chromosomes 3, 5, 7 and 17.2 However, in this patient’s karyotype the deletions and monosomies often found in people with therapy related haematological neoplasms were not present. On the other hand, trisomy 8, frequently observed in myelodysplastic syndromes,2 was found.

We feel that this young man with non-seminomatous primary mediastinal germ cell tumour and severe myelodysplastic syndrome with cytogenetic abnormalities beginning after chemotherapy treatment, is similar to those patients reported by Nichols et al.1

Departments of Internal Medicine,1 Genetics and 2Haematology, Hospital Ramón y Cajal, Madrid, Spain.

Doxycycline-induced parotitis

Sir,

Sialadenitis is an uncommon side effect of drugs and chemicals such as nifedipine,1,2 alpha-methyl dopa,3 phenylbutazone,4 alpha interferon,5 H2 receptor antagonists,6 oxypHENbutazone,7 iodine compounds8 and nitrofurantoin.9 To our knowledge, no cases of doxycycline-induced sialadenitis have been described until now.

An 18 year old female developed serum sickness while receiving doxycycline for inflammatory acne. She had been taking doxycycline 200 mg/day orally for 15 days when she voluntarily discontinued the treatment for 1 week. Forty eight hours after reintroducing this drug, she developed fever (38.2°C), chills, generalized urticaria, hand and foot oedema, and arthralgia in both knees, ankles and wrists. She had not received any other medication during the previous 3 months. Physical examination also revealed bilateral cervical lymphadenopathy up to 2 cm in diameter. Seventy-two hours later, she developed bilateral painful parotid swelling. There was tenderness, reddening and an increased temperature of the skin over the glands. Simultaneously, a recrudescence of urticarial lesions was observed. Other studies showed mild leukocytosis (12,700/mm3), elevated ESR (52 mm in the first hour), hypocomplementaemia (C4, 10 mg/dl) and proteinuria (1.6 g/l) and haematuria (33 red cells per high power field). Serum protein electrophoresis and serum immunoglobulins were within normal limits. Antinuclear antibodies and hepatitis B surface antigen were not detected in serum. She was treated with methylprednisolone 80 mg daily intravenously and hydroxyzine 100 mg/day orally. The parotitis resolved in 24 hours and the rest of the clinical manifestations in 5 days.

The mechanism of drug-induced sialadenitis remains unclear in most cases. Either oedema and spasm of smooth muscle in the salivary gland or a hypersensitivity reaction could be responsible.1,3–5,7–9 In the case reported here, the association between serum sickness and parotitis during doxycycline therapy points to an immunological pathogenesis.

Carmen Vidal Pan
Arturo González Quintela1
Departments of Allergy and 1Internal Medicine, Hospital Puerta de Hierro, c/ San Martín de Porres 4, 28035 Madrid, Spain.
Crohn’s disease in the elderly

Sir,
When faced with the symptoms of altered bowel habit and weight loss in an elderly patient, malignant disease is usually suspected. It is, however, always worth considering Crohn’s disease, as the following case illustrates.

A frail 80 year old woman presented with a 2 month history of constipation, rectal bleeding and weight loss of 1 kg. Her haemoglobin was 10 g/dl and both erythrocyte sedimentation rate (ESR) and acute phase proteins (C-reactive protein and alpha-1-acid glycoprotein) were raised. Barium enema showed gross deformity of the rectosigmoid region typical of diverticular disease along with an adjacent area of mucosal irregularity raising the possibility of co-existent malignancy – biopsies taken at flexible sigmoidoscopy however revealed active Crohn’s disease at this site.

In view of her general condition, further gastrointestinal investigations were not performed. She was treated with sulphasalazine 3 g daily and Colifoam enemas. At review one month later her bowel habit was normal, her ESR had fallen, and she had gained 2 kg in weight.

This case illustrates the unexpected finding of colonic Crohn’s disease during the investigation of an elderly patient suspected of having malignant disease. Crohn’s disease in the elderly predominantly affects females,1 favours the recto-sigmoid junction,2 and is most commonly misdiagnosed as diverticular disease.3 Colonic disease usually responds well to medical therapy with a low recurrence rate.4

Both general physicians and geriatricians should be alert to the possibility of Crohn’s disease in their elderly patients presenting with weight loss and bowel disturbance.

I. Gillanders
B. Danesh
Gastroenterology Unit,
Stobhill General Hospital,
Balornock Road,
Glasgow G21 3UW, UK.

References

Doxycycline-induced parotitis.

C. Vidal Pan and A. González Quintela

doi: 10.1136/pgmj.67.785.313-a

Updated information and services can be found at:
[http://pmj.bmj.com/content/67/785/313.2.citation](http://pmj.bmj.com/content/67/785/313.2.citation)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)